Reducing recurrence of advanced melanoma with pembrolizumab

Bookmark and Share
Published: 25 Apr 2018
Views: 4162
Prof Alex Eggermont - Paris-Sud University, Paris, France

Prof Eggermont speaks with ecancer at AACR 2018 about reducing recurrence of advanced melanoma with pembrolizumab.

In the KEYNOTE-054 trial, a one year course of 200mg pembrolizumab every 3 weeks improved the 12 month recurrence free survival rate from 61% on placebo to 75%.

For more on the trial results, read here or watch Prof Eggermont present the findings in a press session here.